Longevity

STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial

Structured plan for STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial

Retro Biosciences Secures $1.8 Billion Valuation in Landmark Longevity Funding Round

Retro Biosciences has achieved a $1.8 billion valuation after its latest fundraising round, signaling significant investor confidence in the longevity sector. This development presents key strategic considerations for pharmaceutical companies and regulatory bodies.

STAT+: The Woman Behind the World’s Biggest Longevity Competition

Discover the pivotal role of Jamie Justice in the world's largest longevity competition and its implications for the pharmaceutical industry.

Guarding Biotech from China: Big Bets in Longevity

This article examines the strategic measures to protect biotech from Chinese influence and the growing investments in longevity research.